Stage at diagnosis and stage-specific survival of breast cancer in Latin America and the Caribbean: A systematic review and meta-analysis

Autoři: Lívia Lovato Pires de Lemos aff001;  Mirian Carvalho de Souza aff003;  Daniela Pena Moreira aff001;  Paulo Henrique Ribeiro Fernandes Almeida aff004;  Brian Godman aff005;  Stéphane Verguet aff007;  Augusto Afonso Guerra, Junior aff002;  Mariangela Leal Cherchiglia aff001
Působiště autorů: Programa de Pós-Graduação em Saúde Pública, Faculdade de Medicina, Universidade Federal de Minas Gerais, Belo Horizonte, Minas Gerais, Brazil aff001;  SUS Collaborating Centre for Technology Assessment and Excellence in Health, Faculdade de Farmácia, Universidade Federal de Minas Gerais, Belo Horizonte, Minas Gerais, Brazil aff002;  Divisão de Pesquisa Populacional, Instituto Nacional de Câncer José Alencar Gomes da Silva, Rio de Janeiro, Rio de Janeiro, Brazil aff003;  Programa de Pós-Graduação em Medicamentos e Assistência Farmacêutica, Faculdade de Farmácia, Universidade Federal de Minas Gerais, Belo Horizonte, Minas Gerais, Brazil aff004;  Strathclyde Institute of Pharmacy and Biomedical Sciences, Strathclyde University, Glasgow, Scotland aff005;  Division of Clinical Pharmacology, Karolinska University Hospital Huddinge, Karolinska Institutet, Huddinge, Sweden aff006;  Department of Global Health and Population, Harvard T.H. Chan School of Public Health, Boston, Massachusetts, United States of America aff007
Vyšlo v časopise: PLoS ONE 14(10)
Kategorie: Research Article



Female breast cancer is the most common cancer in Latin American and Caribbean (LAC) countries and is the leading cause of cancer deaths. The high mortality-to-incidence ratio in the regions is associated with mainly the high proportion of advanced stage diagnosis, and also to inadequate access to health care. In this study we aimed to systematically review the proportion of advanced stage (III-IV) at diagnosis (pas) and the five-year stage-specific survival estimates of breast cancer in LAC countries.


We searched MEDLINE, Embase, and LILACS (Latin American and Caribbean Health Science Literature) to identify studies, in any language, indexed before Nov 5, 2018. We also conducted manual search by reviewing citations of papers found. pas was summarized by random effects model meta-analysis, and meta-regression analysis to identify sources of variation. Stage-specific survival probabilities were described as provided by study authors, as it was not possible to conduct meta-analysis. PROSPERO CRD42017052493.


For pas we included 63 studies, 13 of which population-based, from 22 countries comprising 221,255 women diagnosed from 1966 to 2017. The distribution of patients by stage varied greatly in LAC (pas 40.8%, 95%CI 37.0% to 44.6%; I2 = 99%; p<0.0001). The heterogeneity was not explained by any variable included in the meta-regression. There was no difference in pas among the Caribbean (pas 43.0%, 95%CI 33.1% to 53.6%), Central America (pas 47.0%, 95%CI 40.4% to 53.8%) and South America (pas 37.7%, 95%CI 33.1% to 42.5%) regions. For 5-year stage-specific survival we included 37 studies, comprising 28,988 women from ten countries. Seven of these studies were included also for pas. Since we were unable to adjust for age, comparability between countries and regions was hampered, and as expected, the results varied widely from study to study.


LAC countries should look to address concerns with early detection and diagnosis of breast cancer, and wherever viable implement screening programs and to provide timely treatment.

Klíčová slova:

Breast cancer – Cancer detection and diagnosis – Cancer screening – Cancer treatment – Caribbean – Latin American people – Systematic reviews


1. Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68: 394–424. doi: 10.3322/caac.21492 30207593

2. Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J, Jemal A. Global cancer statistics, 2012. CA Cancer J Clin. 2015;65: 87–108. doi: 10.3322/caac.21262 25651787

3. Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68: 394–424. doi: 10.3322/caac.21492 30207593

4. World Bank Country and Lending Groups–World Bank Data Help Desk [Internet]. [cited 29 Nov 2018].

5. Economic Commission for Latin America and the Caribbean (ECLAC). Social Panorama of Latin America. United Nations;

6. Lu G, Li J, Wang S, Pu J, Sun H, Wei Z, et al. The fluctuating incidence, improved survival of patients with breast cancer, and disparities by age, race, and socioeconomic status by decade, 1981–2010. Cancer Manag Res. 2018;10: 4899–4914. doi: 10.2147/CMAR.S173099 30464592

7. Allemani C, Matsuda T, Di Carlo V, Harewood R, Matz M, Nikšić M, et al. Global surveillance of trends in cancer survival 2000–14 (CONCORD-3): analysis of individual records for 37 513 025 patients diagnosed with one of 18 cancers from 322 population-based registries in 71 countries. Lancet. 2018;391: 1023–1075. doi: 10.1016/S0140-6736(17)33326-3 29395269

8. Goss PE, Lee BL, Badovinac-Crnjevic T, Strasser-Weippl K, Chavarri-Guerra Y, St Louis J, et al. Planning cancer control in Latin America and the Caribbean. Lancet Oncol. 2013;14: 391–436. doi: 10.1016/S1470-2045(13)70048-2 23628188

9. Justo N, Wilking N, Jönsson B, Luciani S, Cazap E. A review of breast cancer care and outcomes in Latin America. Oncologist. 2013;18: 248–256. doi: 10.1634/theoncologist.2012-0373 23442305

10. Cazap E. Breast Cancer in Latin America: A Map of the Disease in the Region. American Society of Clinical Oncology Educational Book. 2018; 451–456. doi: 10.1200/EDBK_201315 30231404

11. Moher D, PRISMA-P Group, Shamseer L, Clarke M, Ghersi D, Liberati A, et al. Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015 statement. Syst Rev. 2015;4. doi: 10.1186/2046-4053-4-1 25554246

12. United Nations Statistics Division. UNSD—Methodology [Internet]. [cited 28 Nov 2018].

13. Ouzzani M, Hammady H, Fedorowicz Z, Elmagarmid A. Rayyan—a web and mobile app for systematic reviews. Syst Rev. 2016;5. doi: 10.1186/s13643-016-0384-4 27919275

14. Eng A, McCormack V, dos-Santos-Silva I. Receptor-Defined Subtypes of Breast Cancer in Indigenous Populations in Africa: A Systematic Review and Meta-Analysis. PLoS Med. 2014;11: e1001720. doi: 10.1371/journal.pmed.1001720 25202974

15. Jedy-Agba E, McCormack V, Adebamowo C, Dos-Santos-Silva I. Stage at diagnosis of breast cancer in sub-Saharan Africa: a systematic review and meta-analysis. Lancet Glob Health. 2016;4: e923–e935. doi: 10.1016/S2214-109X(16)30259-5 27855871

16. Chubak J, Boudreau DM, Wirtz HS, McKnight B, Weiss NS. Threats to validity of nonrandomized studies of postdiagnosis exposures on cancer recurrence and survival. J Natl Cancer Inst. 2013;105: 1456–1462. doi: 10.1093/jnci/djt211 23940288

17. Wells GA, Shea B, O’Connell D, Peterson J, Welch V, Losos M, et al. The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses. In: The Ottawa Hospital—Research Institute [Internet]. [cited 21 Nov 2017].

18. Schwarzer G, Carpenter JR, Rücker G. Meta-Analysis with R. Springer; 2015.

19. Schwarzer G. meta: An R Package for Meta-Analysis. 2007.

20. Elizalde R, Bustos J, Perrier GM, Naso B, Loza J, Storino C, et al. Caracteristicas Epidemiologicas del Cancer de Mama en el Area Metropolitana de Buenos Aires y La Plata: Estudio de una serie de 4.041 casos del Registro de Cáncer de Mama (RCM). Revista Latinoamericana de Mastologia. 2013;7.

21. Pardo C, Murillo R, Piñeros M, Castro MÁ. Casos nuevos de cáncer en el Instituto Nacional de Cancerología, Colombia, 2002. Revista Colombiana de Cancerología. 2003;7: 4–19.

22. Ortiz-Barboza A, Gomez L, Cubero C, Bonilla G, Mena H. Cancer survival in Costa Rica, 1995–2000. IARC Sci Publ. 2011;9: 85–88.

23. Garrote LF, Alvarez YG, Babie PT, Yi MG, Alvarez MG, Cicili ML. Cancer survival in Cuba, 1994–1995. IARC Sci Publ. 2011;10: 89–95.

24. Ferri N, Contreras AC, Payares E, Agüero B, Ferri F, Ferri F, et al. Cirugía del carcinoma mamario revisión de 20 años. Revista Venezolana de Oncología. 2012;24: 132–142.

25. Cueva P, Yépez J. Cancer Epidemiology in Quito 2006–2010. Sociedad de Lucha Contra el Cáncer—Solca Quito—Registro Nacional De Tumores. 2014;15: 8–241.

26. Cueva P, Yépez J. Epidemiología del Cáncer en Quito 2003–2005. Sociedad de Lucha Contra el Cáncer—Solca Quito—Registro Nacional De Tumores. 2009;

27. Martínez F, Abril L, Pérez L. Sexto Informe Registro de Tumores Cuenca 2005–2009. Instituto del Cáncer SOLCA Cuenca Epidemiología del Cáncer en el Cantón Cuenc. 2015;1: 1–400.

28. Díaz-Vélez C. Informe del registro Hospitalario de Cancer 2007–2012. Red Asistencial Lambayeque; 2013.

29. Moreno de Miguel LF, Pérez-Braojo I, Sánchez-Varela I, Rodríguez-Díaz R. Cirugía conservadora+ radioterapia en el cáncer temprano de mama. Rev Cubana de Oncol. 1998;14: 143–148.

30. Gonzáles-Longoria Boada LB, Lemes-Báez JJ. Supervivencia del cáncer de mama. Rev Arch Bibl Mus. 2011;15: 983–992.

31. Fernandez-Garrote L, Graupera-Boschmonar M, Galan-Alvarez Y, Lezcano-Cicilli M, Martin-Garcia A, Camacho-Rodriguez R. Cancer survival in Cuba. IARC Sci Publ. 1998;8: 51–59.

32. Nemesure B, Wu S-Y, Hambleton IR, Leske MC, Hennis AJ, Barbados National Cancer Study Group. Risk factors for breast cancer in a black population—the Barbados National Cancer Study. Int J Cancer. 2009;124: 174–179. doi: 10.1002/ijc.23827 18814239

33. Mungrue K, Chase H, Gordon J, Knowles D, Lockhart K, Miller N, et al. Breast Cancer in the Bahamas in 2009–2011. Breast Cancer. 2016;10: BCBCR.S32792.

34. Palazzo A, Perinetti A, Vacchino M. Estadio clínico del cáncer de mama y nivel socioeconómico en el partido de General Pueyrredón, Argentina, 2013. Revista Argentina de Salud Pública. 2016;7: 16–20.

35. Wang Q, Li J, Zheng S, Li J-Y, Pang Y, Huang R, et al. Breast cancer stage at diagnosis and area-based socioeconomic status: a multicenter 10-year retrospective clinical epidemiological study in China. BMC Cancer. 2012;12: 122. doi: 10.1186/1471-2407-12-122 22455370

36. Kweon S-S, Kim M-G, Kang M-R, Shin M-H, Choi J-S. Difference of stage at cancer diagnosis by socioeconomic status for four target cancers of the National Cancer Screening Program in Korea: Results from the Gwangju and Jeonnam cancer registries. J Epidemiol. 2017;27: 299–304. doi: 10.1016/ 28279589

37. Walters S, Maringe C, Butler J, Rachet B, Barrett-Lee P, Bergh J, et al. Breast cancer survival and stage at diagnosis in Australia, Canada, Denmark, Norway, Sweden and the UK, 2000–2007: a population-based study. Br J Cancer. 2013;108: 1195–1208. doi: 10.1038/bjc.2013.6 23449362

38. World Health Organization. Cancer country profiles 2014. In: World Health Organization [Internet]. [cited 19 Jul 2018].

39. Maffuz-Aziz A, Labastida-Almendaro S, Sherwell-Cabello S, Ruvalcaba-Limón E, Domínguez-Reyes CA, Tenorio-Torres JA, et al. Supervivencia de pacientes con cáncer de mama. Análisis por factores pronóstico, clínicos y patológicos. Ginecol Obstet Mex. 2016;84: 498–506.

40. Agudelo–Botero M. Niveles, tendencias e impacto de la mortalidad por cáncer de mama en Costa Rica según provincias, 2000–2009. Población y Salud en Mesoamérica. Julio–diciembre, 2011;9.

41. Silva GAE, de Souza-Júnior PRB, Damacena GN, Szwarcwald CL. Early detection of breast cancer in Brazil: data from the National Health Survey, 2013. Rev Saude Publica. 2017;51: 14s.

42. Agudelo Botero M, Botero MA. Determinantes sociodemográficos del acceso a la detección del cáncer de mama en México: una revisión de las encuestas nacionales. Salud Colect. 2013;9: 79–90.

43. Cazap E, Buzaid AC, Garbino C, de la Garza J, Orlandi FJ, Schwartsmann G, et al. Breast cancer in Latin America: results of the Latin American and Caribbean Society of Medical Oncology/Breast Cancer Research Foundation expert survey. Cancer. 2008;113: 2359–2365. doi: 10.1002/cncr.23834 18837031

44. Caplan L. Delay in breast cancer: implications for stage at diagnosis and survival. Front Public Health. 2014;2: 87. doi: 10.3389/fpubh.2014.00087 25121080

45. Rezende MCR, Koch HA, de Figueiredo JA, Thuler LCS. Factors leading to delay in obtaining definitive diagnosis of suspicious lesions for breast cancer in a dedicated health unit in Rio de Janeiro. Rev Bras Ginecol Obstet. 2009;31: 75–81. 19407912

46. Bright K, Barghash M, Donach M, de la Barrera MG, Schneider RJ, Formenti SC. The role of health system factors in delaying final diagnosis and treatment of breast cancer in Mexico City, Mexico. Breast. 2011;20 Suppl 2: S54–9.

47. Gage JC, Ferreccio C, Gonzales M, Arroyo R, Huivín M, Robles SC. Follow-up care of women with an abnormal cytology in a low-resource setting. Cancer Detect Prev. 2003;27: 466–471. 14642555

48. Yoffe de Quiroz I. Delayed diagnose of patients with cancer. Anales de la Facultad de Ciencias Médicas. 2005;

49. Fundación Universitaria de Ciencias de la Salud, Sánchez G, Niño CG, Fundación Universitaria de Ciencias de la Salud, Estupiñán AC, Fundación SIMMON. Determinantes del tratamiento oportuno en mujeres con cáncer de mama apoyadas por seis organizaciones no gubernamentales en Colombia. Rev Fac Nac Salud Pública. 2016;34. doi: 10.17533/udea.rfnsp.v34n3a04

50. Rivera-Franco MM, Leon-Rodriguez E. Delays in Breast Cancer Detection and Treatment in Developing Countries. Breast Cancer. 2018;12: 1178223417752677. doi: 10.1177/1178223417752677 29434475

51. de Quiroz IY. Retardo en el diagnóstico de los pacientes con cáncer. Anales de la Facultad de Ciencias Médicas. 2015. pp. 22–28.

52. Paulino E, de Melo AC, Nogueira-Rodrigues A, Thuler LCS. Gynecologic cancer in Brazil and the law of sixty days. J Gynecol Oncol. 2018;29: e44. doi: 10.3802/jgo.2018.29.e44 29533026

53. Chavez-MacGregor M, Clarke CA, Lichtensztajn DY, Giordano SH. Delayed Initiation of Adjuvant Chemotherapy Among Patients With Breast Cancer. JAMA Oncol. 2016;2: 322–329. 26659132

54. Trufelli DC, de Matos LL, Santi PX, Del Giglio A. Adjuvant treatment delay in breast cancer patients. Rev Assoc Med Bras. 2015;61: 411–416. doi: 10.1590/1806-9282.61.05.411 26603003

55. Hortobagyi GN, Connolly JL, D’Orsi CJ, A EME, Rugo HS, Solin LJ, et al. Breast. In: Amin MB, editor. AJCC Cancer Staging Manual, Eighth Edition. The American College of Surgeons; 2017. pp. 587–636.

56. Feinstein AR, Sosin DM, Wells CK. The Will Rogers phenomenon. Stage migration and new diagnostic techniques as a source of misleading statistics for survival in cancer. N Engl J Med. 1985;312: 1604–1608. doi: 10.1056/NEJM198506203122504 4000199

57. Atun R, de Andrade LOM, Almeida G, Cotlear D, Dmytraczenko T, Frenz P, et al. Health-system reform and universal health coverage in Latin America. Lancet. 2015;385: 1230–1247. doi: 10.1016/S0140-6736(14)61646-9 25458725

Článek vyšel v časopise


2019 Číslo 10
Nejčtenější tento týden